X4P-001-204 A phase 1b trial of Mavorixafor, an oral CXCR4 antagonist, in combination with Ibrutinib in patients with Waldenstrom’s Macroglobulinemia (WM) whose tumors express mutations in MYD88 and CXCR4 A study of Mavorixafor in combination with Ibrutinib in participants with Waldenstrom's Macroglobulinemia (WM) whose Tumors Express Mutations in MYD88 and CXCR4 (Aktiv)
Erstlinie
GCT3013-06 A Randomized, Open-Label, Multicenter, Global, Phase 2 Trial to Assess the Efficacy and Safety of Epcoritamab (GEN3013, DuoBody®-CD3×CD20) Plus Lenalidomide or Epcoritamab Alone as First-line Therapy in Anthracycline- Ineligible Subjects With Diffuse Large B-cell Lymphoma (Aktiv)
GLA 2018-03 - COPA-R-CHOP Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL (Aktiv)
MOR208C310 - frontMIND Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase-3-Studie zur Wirksamkeit und Sicherheit von Tafasitamab plus Lenalidomid zusätzlich zu R-CHOP versus R-CHOP bei zuvor unbehandelten, hochintermediären und hochriskanten Patienten mit diffusem großzelligem B-Zell-Lymphom (DLBCL) (Aktiv)
OLYMPIA-3 A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an anti CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3) (Aktiv)
Pola-R-ICE / GLA 2017-R2 (#1245) An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL) (Aktiv)
SkyGlo GO44145 A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (Aktiv)
Zweitlinie oder später
Amgen 20180257 A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients (Aktiv)
CC-220-NHL-001 A Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and preliminary efficacy of CC-220, alone and in combination with an anti-CD20 Monoclonal Antibody (MAB) in subjects with relapsed or refractory Lymphomas (Aktiv)
CITADEL-202 The purpose of this study is to assess the safety and efficacy of INCB050465 in subjects with relapsed or refractory diffuse large B-cell lymphoma. (Aktiv)
CITADEL-204 The purpose of this study is to evaluate the safety and efficacy of two INCB050465 treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor. (Aktiv)
CYTB323A12101 Phase I/II, open label, multicenter study of rapcaptagene autoleucel in adult patients with CLL/SLL, 3L+ DLBCL, ALL and 1L HR LBCL (Aktiv)
DALY 2-EU Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (Aktiv)
LYMRIT-37-05 Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) (Aktiv)
NIVEAU Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma (Aktiv)
Pola-R-ICE / GLA 2017-R2 (#1245) An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL) (Aktiv)
TIGER-CTL019 - TIGER Mit Ponatinib auf dem Weg zur therapiefreien Remission bei chronischer myeloischer Leukämie - PONTrack (Aktiv)